Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹16 Cr.
Stock P/E
-20.3
P/B
4.9
Current Price
₹23
Book Value
₹ 4.7
Face Value
10
52W High
₹24.4
52W Low
₹ 8.3
Dividend Yield
0%

Hemo Organic Overview

Business

Hemo Organic Ltd. is an Indian company primarily engaged in the trading sector. Its core business model revolves around procuring various goods from suppliers and selling them to customers, aiming to generate profit from the difference between buying and selling prices. As a trading entity, it acts as an intermediary, facilitating the movement of products across the supply chain, often connecting producers with end-users or other businesses. The specific types of goods traded are not detailed, but it operates within the general trading industry.

Revenue Mix

Information regarding specific key business segments or a detailed revenue mix for Hemo Organic Ltd. is not publicly available. As a pure-play trading company, its revenues are likely consolidated from its various trading activities without distinct segment reporting based on product categories or geographies.

Industry

The trading industry in India is highly fragmented and competitive, characterized by numerous small to medium-sized players alongside larger diversified conglomerates. Barriers to entry can be relatively low, particularly for general trading activities. Hemo Organic Ltd., as a dedicated trading company, operates in a segment where differentiation often comes from efficient supply chain management, strong relationships with suppliers and customers, competitive pricing, and timely execution. Without further details on its specific niche or scale, it is likely positioned as a participant in a competitive market, where success hinges on operational efficiency and market acumen.

MOAT

Given its classification as a trading company, Hemo Organic Ltd. is unlikely to possess strong, durable competitive advantages (moats) like proprietary technology, patents, strong brands, significant network effects, or high switching costs that are common in other sectors. Any potential advantages would likely stem from:

Supplier/Customer Relationships: Long-standing, trusted relationships can provide better terms or preferential access.

Efficient Logistics & Supply Chain: Superior efficiency in procurement, storage, and distribution can lead to cost advantages.

Niche Expertise: Specialization in particular product categories or geographies where it has deep market knowledge.

However, these advantages are generally less sticky and more susceptible to competition than traditional moats.

Growth Drivers

Key factors that could drive growth for Hemo Organic Ltd. over the next 3-5 years include:

Expansion of Product Portfolio: Identifying and entering new profitable product categories for trading.

Geographical Expansion: Expanding trading activities into new domestic or international markets.

Increased Demand for Traded Goods: Growth in the underlying industries that rely on the products Hemo Organic trades.

Supply Chain Optimization: Improving efficiency in procurement, inventory management, and logistics to enhance margins and competitiveness.

Strengthening Relationships: Deepening ties with key suppliers and customers to secure better terms and consistent business flow.

Risks

Hemo Organic Ltd. faces several inherent risks typical of the trading industry:

Commodity Price Volatility: Fluctuations in the prices of goods traded can significantly impact margins and inventory values.

Competition: Intense competition from numerous domestic and international players can drive down margins.

Credit Risk: Risk of non-payment or delayed payment from customers, especially in bulk trading.

Inventory Risk: Risk of obsolescence, damage, or decline in value of stored inventory.

Forex Fluctuations: If involved in international trade, currency exchange rate volatility can impact profitability.

Supply Chain Disruptions: Global events, geopolitical issues, or logistics challenges can disrupt supply and demand.

Regulatory Changes: Changes in trade policies, tariffs, or import/export regulations can impact operations.

Management & Ownership

As is common with many Indian companies, Hemo Organic Ltd. is likely promoter-led. The quality of management is critical in the trading sector, requiring astute decision-making in procurement, sales, risk management, and logistics. Without specific information, it's assumed that the promoters hold a significant stake, aligning their interests with the company's performance. The ability of the management team to identify profitable trading opportunities, manage inventory effectively, and mitigate risks will be paramount to the company's success.

Outlook

The outlook for Hemo Organic Ltd. is intrinsically linked to its operational efficiency and market acumen within the highly competitive trading sector. The bull case hinges on the management's ability to consistently identify lucrative trading opportunities, maintain strong and efficient supply chains, effectively manage inventory and credit risks, and foster robust relationships with both suppliers and customers. Successful execution in these areas could lead to stable or growing margins and market share. Conversely, the bear case highlights the significant inherent risks: intense price competition potentially eroding margins, exposure to volatile commodity prices, credit defaults, and the lack of strong enduring competitive moats, which can lead to unpredictable earnings and susceptibility to broader economic downturns or specific market disruptions. Its future performance will largely depend on its agility and disciplined risk management in navigating this dynamic industry.

Hemo Organic Share Price

Live · BSE · Inception: 1992
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Hemo Organic Quarterly Results

#(Fig in Cr.) Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net Sales 0 0 0 2 0 0 0 1 0 1
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 3 0 0 0 1 0 1
Total Expenditure 0 0 0 2 0 0 0 1 0 1
Operating Profit -0 -0 -0 0 -0 -0 -0 -0 -0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -0 -0 -0 0 -0 -0 -0 -0 -0 0
Provision for Tax 0 0 0 -0 -0 -0 0 0 0 0
Profit After Tax -0 -0 -0 0 -0 -0 -0 -1 -0 0
Adjustments 0 0 0 0 -0 0 -0 0 0 0
Profit After Adjustments -0 -0 -0 0 -0 -0 -0 -1 -0 0
Adjusted Earnings Per Share -0 -0.2 -0.2 1.1 -0.2 -0.1 -0.4 -1.5 -0.2 0

Hemo Organic Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 0 1 0 0 0 0 0 0 0 2 1 2
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 0 1 0 0 0 0 0 0 0 2 1 2
Total Expenditure 0 1 0 0 0 0 0 0 0 2 1 2
Operating Profit -0 -0 -0 -0 -0 -0 -0 -0 -0 0 -0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses -1 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -1 -0 -0 -0 -0 -0 -0 -0 -0 0 -0 0
Provision for Tax 0 0 0 0 0 0 0 0 0 -0 0 0
Profit After Tax -1 -0 -0 -0 -0 -0 -0 -0 -0 0 -1 -1
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -1 -0 -0 -0 -0 -0 -0 -0 -0 0 -1 -1
Adjusted Earnings Per Share -2.4 -0.2 -0.4 -0.3 -0.1 -0.1 -0.2 -0.2 -0.8 0.5 -2.2 -2.1

Hemo Organic Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 0 0 0 0 0 0 0 -0 -0 -0 0
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 1 1 3
Other Non-Current Liabilities -0 0 -0 -0 -0 -0 -0 -0 -0 -0 0
Total Current Liabilities 0 1 1 1 0 0 0 0 0 4 2
Total Liabilities 0 1 1 1 0 0 0 0 1 5 4
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0 0 0 0 0 0
Total Current Assets 0 1 1 1 0 0 0 0 1 5 4
Total Assets 0 1 1 1 0 0 0 0 1 5 4

Hemo Organic Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities -1 -0 -0 -0 0 -0 -0 0 -1 -0 -1
Cash Flow from Investing Activities 1 0 0 0 0 0 0 0 0 0 -1
Cash Flow from Financing Activities 0 0 0 0 0 0 0 0 1 0 2
Net Cash Inflow / Outflow -0 0 -0 -0 0 -0 -0 0 0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0 0 0

Hemo Organic Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) -2.42 -0.23 -0.43 -0.35 -0.06 -0.14 -0.18 -0.16 -0.76 0.47 -2.25
CEPS(Rs) -2.24 -0.23 -0.43 -0.35 -0.06 -0.14 -0.18 -0.16 -0.76 0.47 -2.24
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 1.23 1.16 0.74 0.39 0.33 0.19 0.01 -0.15 -0.91 -0.44 -2.68
Core EBITDA Margin(%) -50.19 -13.14 -170.39 -219.71 -6.84 -591.47 -910.67 -1135.42 -1089.29 -1.73 -53.39
EBIT Margin(%) -741.48 -13.14 -170.34 -219.71 -6.84 -591.47 -910.67 -1135.42 -1088.39 1.17 -53.24
Pre Tax Margin(%) -741.48 -13.14 -170.34 -219.71 -7.87 -593.22 -913.15 -1137.5 -1179.02 1.06 -53.64
PAT Margin (%) -741.48 -13.14 -170.34 -219.71 -7.87 -593.22 -913.15 -1137.5 -1179.02 6.79 -83.76
Cash Profit Margin (%) -686.77 -13.14 -170.34 -219.71 -7.87 -593.22 -913.15 -1137.5 -1179.02 6.79 -83.69
ROA(%) -101.27 -11.32 -15.99 -14.38 -4.75 -47.99 -65.16 -36.11 -46.85 5.83 -16.99
ROE(%) -99.33 -19.17 -44.9 -61.38 -17.52 -53.35 -180.16 0 0 0 0
ROCE(%) -96.61 -19.17 -39.88 -43.09 -11.35 -44.09 -89.29 -484.9 -53.8 2.51 -23.54
Receivable days 0 441.72 3039.98 4876.84 530.41 3067.58 3370.67 4500.64 1156.1 196.55 963.79
Inventory Days 0 18.31 113.98 87.88 2.26 83.43 513.46 1223.62 0 214.12 378.08
Payable days 3.75 197.14 2850.99 3607.95 793.49 7287.47 3748.33 0 2538.3 310.2 1020.02
PER(x) 0 0 0 0 0 0 0 0 0 18.97 0
Price/Book(x) 15.33 15.12 19.67 0 35.37 76.9 5177.65 -48.06 -11.21 -20.52 -4.36
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 56.87 10.04 58.49 64.58 14.41 629.69 2607.01 495.71 207.34 1.9 7.3
EV/Core EBITDA(x) -116.92 -76.38 -34.34 -29.39 -210.59 -106.46 -286.27 -43.66 -19.05 162.4 -13.73
Net Sales Growth(%) -29.91 439.27 -85.49 -37.12 407.47 -97.09 -15.37 -29.72 366.67 0 -61.52
EBIT Growth(%) -679.37 90.44 -88.16 18.89 84.19 -151.61 -30.31 12.38 -347.34 111.57 -1853.9
PAT Growth(%) -679.37 90.44 -88.16 18.89 81.81 -119.34 -30.28 12.46 -383.7 162.06 -574.74
EPS Growth(%) -679.48 90.62 -88.17 18.89 81.8 -119.21 -30.27 12.45 -383.81 162.06 -574.73
Debt/Equity(x) 0 0 0.32 0.61 0.02 0.53 10.21 -0.69 -3.92 -9.77 -2.95
Current Ratio(x) 4.28 1.57 1.3 1.1 0.8 0.69 0.48 0.56 6.5 1.29 2.81
Quick Ratio(x) 4.28 1.52 1.26 1.1 0.79 0.67 0.4 0.52 6.5 0.9 2.49
Interest Cover(x) 0 0 0 0 -6.64 -338.52 -368.04 -545 -12.01 10.85 -133.68
Total Debt/Mcap(x) 0 0 0.02 0 0 0.01 0 0.01 0.35 0.48 0.68

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -50% — — —
Operating Profit CAGR — — — —
PAT CAGR — — — —
Share Price CAGR +173% +57% +21% +5%
ROE Average 0% 0% -36% -43%
ROCE Average -24% -25% -130% -82%

Hemo Organic Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 16.85 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 83.15 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 16.8516.8516.8516.8516.8516.8516.8516.8516.8516.85
FII 0000000000
DII 0000000000
Public 83.1583.1583.1583.1583.1583.1583.1583.1583.1583.15
Others 0000000000
Total 100100100100100100100100100100

Hemo Organic Peer Comparison

Hemo Organic Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Hemo Organic Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 16.85%.
  • Company has a low return on equity of 0% over the last 3 years.
  • Debtor days have increased from 310.2 to 1020.02days.
  • Stock is trading at 4.9 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp